HALO
Halozyme Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
HALO fundamentals
Halozyme Therapeutics (HALO) expects to report earnings on Aug 5, 2025, with estimated revenue of 282.66M (YoY +22.36%), and EPS at 1.2 (YoY +31.87%).
Revenue estimate / YoY
282.66M
+22.36%
EPS estimate / YoY
1.2
+31.87%
Report date
Aug 5, 2025
EPS
Revenue
Revenue & Expenses
HALO has released its 2025 Q1 earnings report, with revenue of 264.86M, reflecting a YoY change of 35.22%, and net profit of 118.09M, showing a YoY change of 53.72%. The Sankey diagram below clearly presents HALO's revenue sources and cost distribution.
Key Indicators
Halozyme Therapeutics (HALO) key financial stats and ratios, covering profitability, financial health, and leverage.
Halozyme Therapeutics (HALO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Halozyme Therapeutics (HALO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Halozyme Therapeutics (HALO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Halozyme Therapeutics (HALO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Halozyme Therapeutics (HALO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What is the revenue and EPS growth rate for Halozyme Therapeutics year over year?What is Halozyme Therapeutics’s gross profit margin?What were the key takeaways from Halozyme Therapeutics’s earnings call?What is the market’s earnings forecast for Halozyme Therapeutics next quarter?What does Halozyme Therapeutics do and what are its main business segments?What factors drove the changes in Halozyme Therapeutics’s revenue and profit?Did Halozyme Therapeutics beat or miss consensus estimates last quarter?What guidance did Halozyme Therapeutics’s management provide for the next earnings period?